# A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD

> **NCT02677519** · PHASE4 · UNKNOWN · sponsor: **Rhodes Pharmaceuticals, L.P.** · enrollment: 120 (estimated)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** Aptensio XR

## Key facts

- **NCT ID:** NCT02677519
- **Lead sponsor:** Rhodes Pharmaceuticals, L.P.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2017-04
- **Final completion:** 2017-09
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2016-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02677519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02677519, "A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02677519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*